Micafungin Accord

Micafungin, the active ingredient in Micafungin Accord, is an echinocandin antifungal presented as an intravenous solution for intravenous use. It treats systemic fungal infections, including candidemia and esophageal candidiasis, in adult and pediatric patients.

GNH USA supplies Micafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for safe delivery to clinical sites. Our global network ensures timely availability across multiple regions, supporting critical antifungal therapy needs.

Micafungin is an echinocandin antifungal used to manage invasive fungal infections. - Esophageal candidiasis: effective treatment that clears infection and relieves dysphagia. - Candidemia and invasive candidiasis: rapid fungicidal activity leading to bloodstream clearance. - Peritoneal candidiasis: eradicates infection in intra‑abdominal sites following surgery. - Prophylaxis in hematopoietic stem cell transplantation: prevents breakthrough fungal infections during neutropenia.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever - Chills - Nausea - Headache - Elevated liver enzymes - Rash

Serious or Rare Side Effects: - Hepatic failure - Severe hypersensitivity reactions including anaphylaxis - Acute renal impairment - Severe hypotension

When using Micafungin, clinicians should observe several precautionary measures to ensure patient safety. - Liver function monitoring: assess hepatic enzymes before and during therapy. - Renal function assessment: evaluate creatinine clearance, especially in patients with pre‑existing kidney disease. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Pediatric use: dose adjustments may be required; follow specialist guidance. - Concomitant hepatotoxic drugs: avoid or monitor closely when combined with other agents that affect liver function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce micafungin exposure. - Concurrent use with other hepatotoxic agents: increased risk of liver injury. - Combination with other echinocandins: additive toxicity without added benefit.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin levels. - Immunosuppressants such as cyclosporine or tacrolimus: monitor blood concentrations. - Warfarin: observe INR for potential alterations. - Statins: watch for possible increased muscle toxicity.